WO2013091974A2 - Utilisation d'une combinaison d'acide 2-méthyl-1,4,5,6-tétrahydro-4 pyrimidine carboxylique ou de son dérivé et d'un extrait d'algues bleues pour augmenter la fonction barrière de la peau - Google Patents

Utilisation d'une combinaison d'acide 2-méthyl-1,4,5,6-tétrahydro-4 pyrimidine carboxylique ou de son dérivé et d'un extrait d'algues bleues pour augmenter la fonction barrière de la peau Download PDF

Info

Publication number
WO2013091974A2
WO2013091974A2 PCT/EP2012/071820 EP2012071820W WO2013091974A2 WO 2013091974 A2 WO2013091974 A2 WO 2013091974A2 EP 2012071820 W EP2012071820 W EP 2012071820W WO 2013091974 A2 WO2013091974 A2 WO 2013091974A2
Authority
WO
WIPO (PCT)
Prior art keywords
blue
green algae
acid
skin
formula
Prior art date
Application number
PCT/EP2012/071820
Other languages
German (de)
English (en)
Other versions
WO2013091974A3 (fr
Inventor
Ira Hartmann
Soraya Heinen
Marianne DR. WALDMANN-LAUE
Claudia Jassoy
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Publication of WO2013091974A2 publication Critical patent/WO2013091974A2/fr
Publication of WO2013091974A3 publication Critical patent/WO2013091974A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the barrier function of the skin protects the skin from drying out.
  • This barrier function is caused by the epidermis, which, as the outermost layer, forms the actual protective cover against the environment.
  • the epidermis is a stratified tissue in which the outer layer, the horny layer (stratum corneum) represents the barrier function function important part. It is worn down in contact with the environment and is therefore in a constant process of renewal. In this renewal process, fine dandruff is continuously released to the outside and the celluloid and lipid material, which has hardened from the inside, is subsequently reproduced.
  • Elias Skin Model (PM Elias, Structure and Function of the Stratum Corneum Permeability Barrier, Drug Dev. Res. 13, 1988, 97-105), which is now recognized in the art, describes the horny layer as a two-component system, similar to a brick wall (US Pat. Brick-mortar model).
  • the horny cells (corneocytes) correspond to the bricks
  • the complex lipid membrane in the intercellular spaces corresponds to the mortar.
  • This system essentially represents a physical barrier against hydrophilic substances, but due to its narrow and multi-layered structure, it can also be passed through by lipophilic substances just as easily.
  • the special structure of the horny layer protects the skin and stabilizes its own flexibility by binding a defined amount of water.
  • Various skincare products are known in the art which are capable of improving the epidermal barrier function.
  • these skin care products are usually occlusive in nature, eg. As Vaseline and Vaseline-containing creams, and often have a sticky skin sensation and / or uncomfortable wearing comfort.
  • the ointment or cream is, so to speak, a (second) artificial barrier that is supposed to prevent the loss of water from the skin. Accordingly, this physical barrier - for example, with cleaning agents - can be removed again, whereby the original, impaired state is reached again.
  • the skin care effect may decrease with regular treatment. After discontinuation of the product application, the skin returns to its pre-treatment state very quickly.
  • a sustainable product effect is usually not achieved or only to a limited extent.
  • lipid mixtures such as ceramides or ceramide analogues, which are to be used by the skin to rebuild the natural barrier, are increasingly being added to the topical preparations.
  • these lipids are usually very expensive raw materials, which are also difficult to formulate because of their high melting point.
  • their effect is limited because the topically applied lipids penetrate only to a small extent in the barrier-relevant lipid membranes in the middle stratum corneum and are integrated only to a small extent in these structures.
  • the prior art lacks preparations which have a positive influence on the barrier function and the hydration of the horny layer and strengthen or even restore the physicochemical properties of the horny layer and in particular the lamellae of intercellular lipids.
  • the object of the present invention was to develop topical compositions which strengthen the barrier function of the skin, for example against transepidermal water loss and simultaneously reduce further adverse skin reactions to environmental stress. Another object of the present invention was to develop topical compositions that strengthen the barrier function of the skin. Another object of the present invention was to develop topical compositions that strengthen the barrier function of the skin with a longer lasting effect than the prior art compositions. A further object of the present invention was to develop cost-effective and production-optimized topical compositions which strengthen the barrier function of the skin.
  • the present invention is the non-therapeutic cosmetic use of the active ingredient combination of at least one compound of 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid or its derivative, at least one blue-green algae extract and optionally at least one fucose-containing polysaccharide for stimulation the epidermal synthesis of epidermal synthesis of filaggrin and / or transglutaminicase and / or involucrin.
  • Another object of the present invention is the non-therapeutic cosmetic use of the active ingredient combination of at least one compound of 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid or its derivative, at least one blue-green algae extract and optionally at least one fucose-containing polysaccharide for the regeneration of the skin barrier function.
  • Another object of the present invention is the non-therapeutic cosmetic use of the active ingredient combination of at least one compound of 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid or its derivative, at least one blue-green algae extract and optionally at least one fucose-containing polysaccharide to accelerate the regeneration of the skin barrier function.
  • Another object of the present invention is the non-therapeutic cosmetic use of the active ingredient combination of at least one compound of 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid or its derivative, at least one blue-green algae extract and optionally at least one fucose-containing polysaccharide to improve the appearance of dry skin.
  • Another object of the present invention is the non-therapeutic cosmetic use of the active ingredient combination of at least one compound of 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid or its derivative, at least one blue-green algae extract and optionally at least one fucose-containing polysaccharide to reduce skin dryness.
  • Another object of the present invention is the non-therapeutic cosmetic use of the active ingredient combination of at least one compound of 2-methyl-1, 4,5,6-tetrahydro-4- pyrimidinecarboxylic acid or its derivative, at least one blue-green algae extract and optionally at least one fucose-containing polysaccharide for stimulating the epidermal synthesis of barrier lipids, for regeneration of the skin barrier function, for accelerating the regeneration of the skin barrier function and / or for improving the appearance of dry skin and at the same time for reducing reddening of the skin.
  • a second subject of the invention is a cosmetic agent containing a combination of active ingredients in a cosmetic carrier
  • the active ingredient combination according to the invention necessarily comprises at least one 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid or its derivative.
  • a derivative erfindun accordingly be compounds with the structural unit
  • Preferred 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid or derivatives thereof are preferably from at least one compound of general formula (I) and / or a physiologically acceptable salt and / or an isomeric or stereoisomeric form thereof Selected compounds in which
  • R is a hydrogen atom or a hydroxy group and R 'is a moiety
  • Suitable physiologically acceptable salts of the general compounds of the formula (I) are, for example, the alkali metal, alkaline earth metal, ammonium, triethylamine or tris (2-hydroxyethyl) amine salts and those which are obtained from the reaction of compounds of the formula (I ) with inorganic and organic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, branched or unbranched, substituted or unsubstituted (for example by one or more hydroxy groups) Ci-C4 mono- or dicarboxylic acids, aromatic carboxylic acids and sulfonic acids such as acetic acid, citric acid, benzoic acid, maleic acid , Fumaric, tartaric and p-toluenesulfonic acid.
  • physiologically acceptable salts are the Na, K, Mg, Ca and ammonium salts of the compounds according to the formula (I), and the salts which are obtained by the reaction of compounds of the formula (I) with hydrochloric acid , Acetic acid, citric acid and benzoic acid.
  • amino acid is understood to mean the stereoisomeric forms, for example D and L forms, of the following compounds: asparagine, arginine, aspartic acid, glutamine, glutamic acid, ⁇ -alanine, ⁇ -aminobutyrate, N 8 -acetyllysine, N 8 -acetylornitin, N y -acetyldiaminobutyrate, N a -acetyldiaminobutyrate, histidine, isoleucine, leucine, methionine, phenylalanine, serine, threonine and tyrosine.
  • L-amino acids are preferred.
  • Amino acid residues are derived from the corresponding amino acids. The following amino acids are preferred:
  • the short notation of the amino acids was carried out according to the usual notation.
  • the Dioder tripeptide radicals are acid amides in their chemical nature and decompose on hydrolysis in 2 or 3 amino acids.
  • the amino acids in the di- or tripeptide moiety are linked together by amide bonds.
  • C 1 -C 4 -alkyl groups in the compounds according to the invention are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl.
  • Preferred alkyl groups are methyl and ethyl, methyl is a particularly preferred alkyl group.
  • Preferred C 2 -C 4 hydroxyalkyl groups are Groups 2-hydroxyethyl, 3-hydroxypropyl or 4-hydroxybutyl; 2-hydroxyethyl is a particularly preferred hydroxyalkyl group.
  • R represented by the general formula (I) is preferably a hydrogen atom.
  • Cosmetic skin treatment agents which can be used according to the invention preferably comprise the 2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid and / or derivatives thereof, in particular the compounds of the formula (I) (preferably ectoine) in a total amount of 0.0005 to 10.0% wt .-%, particularly preferably 0.001 to 3.0 wt .-% and most preferably 0.01 to 1, 0 wt .-%, each based on the weight of the total composition.
  • At least one blue-green algae extract must be present in the composition according to the invention.
  • Blue algae - also called cyanobacteria - are bacteria that lack the nucleus, mitochondria, and chloroplasts.
  • the cell envelope of the blue-green algae consists of a cytoplasmic mambrane surrounded by a murein layer and an outer cell wall of lipopolysaccharides and proteins. Blue-green algae also contain pigments for photosynthesis.
  • a blue-green extract of blue-green algae of the order Oscillatoriales (according to the taxonomy database of the National Center for Biotechnology Information of the USA) in the compositions according to the invention. It is particularly preferred to use an extract of the blue-green algae of the genus Spirulina.
  • a blue-green algae extract from Spirulina Platensis can be used very particularly preferably within the scope of the invention.
  • the blue-green extract used according to the invention preferably contains
  • the extracts of a blue-green algae according to the invention can be obtained by conventional extraction methods.
  • Cosmetic skin treatment agents which can be used according to the invention preferably contain the blue-green algae extract in an amount of 0.0001 to 5.0% by weight, preferably 0.001 to 3.0% by weight, particularly preferably 0.005 to 1.0% by weight, based in each case on the weight of the entire composition.
  • the agent according to the invention contains as optional component of the combination of active substances according to the invention at least one fucose-containing polysaccharide.
  • the fucose-containing polysaccharides according to the invention therefore necessarily comprise at least one structural unit of the formula (F1)
  • a bond denoted by * within a general formula of this application is - unless otherwise defined - a free valency of the structure shown.
  • the bonds marked with * according to formula (F1) represent a glycosidic bond to another saccharide residue of the fucose-containing polysaccharide.
  • the structural units of the formula (F1) are derived from L-fucose and / or from D-fucose.
  • the structural units of the formula (F1) are preferably derived from the L-fucose with formation of the preferred structural units of the formula (F1-1)
  • bonds marked with * according to formula (F1-1) represent a glycosidic bond to another saccharide residue of the fucose-containing polysaccharide.
  • the fucose-containing polysaccharide is preferably anionic. It therefore preferably contains in addition to said fucose structural unit additionally at least one structural unit derived from a uronic acid, in particular of galacturonic acid, glucuronic acid or iduronic acid. Particularly preferably, the additional structural unit is derived from the formula (F2)
  • bonds indicated by * according to formula (F2) represent a glycosidic bond to another saccharide residue of the fucose-containing polysaccharide.
  • the fucose-containing polysaccharides according to the invention in addition to the structural unit derived from fucose, additionally contain at least one structural unit which is derived from galactose.
  • the additional galactose structural unit is derived from the formula (F3)
  • bonds indicated by * according to formula (F3) represent a glycosidic bond to another saccharide residue of the fucose-containing polysaccharide.
  • An inventively particularly preferred fucose-containing polysaccharide contains at least one previously defined structural unit of the formula (F1-1) and at least one previously defined structural unit of the formula (F2) at least one previously defined structural unit of the formula (F3).
  • a still preferred fucose Anlagens polysaccharide of this embodiment carries the INCI nomenclature Biosaccharide Gum-1 and is marketed, for example, by the company Solabia under the trade name Fucogel 1000 ® or Fucocert ®.
  • Cosmetic skin treatment agents which can be used according to the invention preferably contain the fucose-containing polysaccharide in an amount of 0.0001 to 2.0% by weight, preferably 0.001 to 1.5% by weight, particularly preferably 0.005 to 0.5% by weight, in each case on the weight of the entire composition.
  • Particularly preferred cosmetic skin treatment agents are those of the embodiments (A) to (F)
  • composition comprising, in a cosmetic carrier, an active ingredient combination of at least one compound of the formula (I) and / or a physiologically tolerable salt and / or an isomeric or stereoisomeric form of these compounds,
  • R is a hydrogen atom or a hydroxy group and R 'is a grouping -COOR or a grouping -CO (NH) R 1 , wherein R is a hydrogen atom, a C- ⁇ - C 4 alkyl radical, an amino acid residue, a dipeptide or a tripeptide radical, and
  • At least one blue-green algae extract of blue-green algae of the genus Spirulina in particular Spirulina platensis, and
  • At least one fucose-containing polysaccharide comprising at least one structural unit of the formula (F1-1) and at least one structural unit of the formula (F2) at least one structural unit of the formula (F3)
  • composition comprising, in a cosmetic carrier, a combination of active ingredients, each based on the total weight of the agent
  • R is a hydrogen atom or a hydroxy group and R 'is a grouping -COOR 1 or a grouping -CO (NH) R 1 , where R is a hydrogen atom, a C 1 -C 4 -alkyl radical, an amino acid radical, a dipeptide radical or a tripeptide radical, and From 0.0001 to 5.0% by weight, preferably from 0.001 to 3.0% by weight, more preferably from 0.005 to 1.0% by weight, of at least one blue-green algae extract of the genus Spirulina, in particular Spirulina platensis, and
  • At least one blue-green algae extract of blue-green algae of the genus Spirulina in particular Spirulina platensis, and
  • At least one fucose-containing polysaccharide comprising at least one structural unit of the formula (F1-1) and at least one structural unit of the formula (F2) at least one structural unit of the formula (F3)
  • At least one blue-green algae extract of blue-green algae of the genus Spirulina in particular Spirulina platensis, and
  • biosaccharides Gum-1 as fucose-containing polysaccharide.
  • biosaccharides Gum-1 as a fucose-containing polysaccharide optionally 0.0001 to 2.0 wt .-%, preferably 0.001 to 1, 5 wt .-%, particularly preferably 0.005 to 0.5 wt .-%, biosaccharides Gum-1 as a fucose-containing polysaccharide.
  • the cosmetic skin treatment agents used according to the invention are in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water In-oil-in-water emulsion, macroemulsion, miniemulsion, microemulsion, PIT emulsion, nanoemulsion, Pickering emulsion, hydrodispersion, a hydrogel, a lipogel, a single- or multiphase solution, a foam, a powder or a Mixture with at least one suitable as a medical adhesive polymer.
  • the skin treatment agents are present as microemulsions.
  • microemulsions are understood as meaning not only the thermodynamically stable microemulsions but also the so-called "PIT" emulsions.
  • PIT phase inversion temperature
  • these emulsions are systems with the 3 Components water, oil and emulsifier, which are present at room temperature as an oil-in-water emulsion. When these systems are heated, microemulsions are formed in a certain temperature range (referred to as the phase inversion temperature or "PIT”) and, on further heating, convert to water-in-oil emulsions.
  • PIT phase inversion temperature
  • O / W emulsions are again formed, but they are also present at room temperature as microemulsions or as very finely divided emulsions having an average particle diameter of less than 400 nm and in particular of about 100-300 nm. According to the invention, those micro- or "PIT" emulsions may be preferred which have an average particle diameter of about 200 nm.
  • the compositions according to the invention contain at least one surface-active substance as emulsifier or dispersant.
  • Suitable emulsifiers are for example adducts of from 4 to 30 mol ethylene oxide and / or 0 to 5 mol propylene oxide onto linear C 8 -C 2 2-fatty alcohols, on C 2 -C 2 2 fatty acids and C 8 -C-
  • the commercially available products Montanov ® 68, Montanov ® 202 or Montanov ® L addition products of 5 to 60 moles of ethylene oxide with castor oil and hydrogenated castor oil, partial esters of polyols having 3-6 carbon atoms with saturated C 8 -C 2 2 fatty acids
  • Sterols in particular cholesterol, lanosterol, beta-sitosterol, stigmasterol, campesterol and ergosterol, and also mycosterols, phospholipids, especially glucose phospholipids, fatty acid esters of sugars and sugar alcohols such as sorbitol, polyglycerols and polyglycerol derivatives, preferably polyglyceryl-2 dipolyhydroxystearate (Dehymuls ® PGPH commercial product) and polyglyceryl-3 diisostearate (Lameform ® TGI commercial product) as well as linear and branched C 8 -C 30 fatty acids and their Na, K, ammonium, Ca, Mg
  • the skin treatment agents used according to the invention preferably contain the emulsifiers in amounts of from 0.1 to 25% by weight, in particular from 0.5 to 15% by weight, based on the total composition.
  • at least one nonionic emulsifier having an HLB value of 8 and below is included.
  • Further preferred emulsifiers with an HLB value of 8 and below are the adducts of 1 or 2 moles of ethylene oxide or propylene oxide with behenyl alcohol, erucyl alcohol, arachidyl alcohol or behenic acid or erucic acid.
  • the monoesters of C 16 -C 3 o fatty acids with polyols such.
  • polyols such as pentaerythritol, trimethylolpropane, diglycerol, sorbitol, glucose or methyl glucose. Examples of such products are z.
  • an emulsifier system is particularly preferably suitable as a mixture
  • o-mono- or diacylglycerides preferably at least one Ci6-i8-mono- or diacylglyceride, particularly preferably selected from hardened palm oil glycerides, can be formulated and stored particularly stable in storage.
  • the at least one salt of a C 2 -2O-alkyl phosphate is present in the inventive compositions used in a total amount from 0.2 to 2.0 wt .-%, preferably 0.3 - 1. 8 wt .-%, particularly preferably 1, 0 - 1, 5 wt .-%, each based on the total weight of the composition.
  • Preferred compositions used according to the invention comprise at least one salt of cetyl phosphate in a total amount of 0.2-2.0% by weight, preferably 0.3-1.8% by weight, more preferably 1.0-0.5% by weight. -%, in each case based on the total weight of the composition.
  • compositions used according to the invention comprise a mixture of dipotassium monocetyl phosphate and potassium dicetyl phosphate in a total amount of 0.2-2.0% by weight, preferably 0.3-1.8% by weight, more preferably 1.0-0.1 , 5 wt .-%, each based on the total weight of the composition.
  • Other suitable additives are thickeners, for.
  • Example natural and synthetic clays and sheet silicates such as bentonite, hectorite, montmorillonite or Laponite ® , or anionic polymers of acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid, where the acidic groups wholly or partly as sodium , Potassium, ammonium, mono- or triethanolammonium salt, and wherein at least one nonionic monomer may be contained.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylates, methacrylates, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. These copolymers can also be present in crosslinked form. Suitable commercial products are NS Sepigel ® 305 Simulgel® ® 600, Simulgel® ®, Simulgel® ® EC and Simulgel® ® EPG SEPPIC. Further particularly preferred anionic homopolymers and copolymers are uncrosslinked and crosslinked polyacrylic acids. Such compounds are for example the commercial products Carbopol ®. A particularly preferred anionic copolymer contains as monomer 80-98% of an unsaturated, optionally substituted C 3 .
  • Suitable nonionic polymers include polyvinyl alcohols, which may be partially saponified, for. B. the commercial products Mowiol ® and vinylpyrrolidone / vinyl ester copolymers and polyvinylpyrrolidones z. B. under the trademark Luviskol ® (BASF) are sold.
  • the skin treatment agents used in the invention preferably contain fatty substances selected from oils, in particular vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils , Isoparaffin oils and synthetic hydrocarbons, di-n-alkyl ethers having a total of 12 to 36 carbon atoms, eg. B.
  • vegetable oils such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives
  • liquid paraffin oils Isoparaffin oils and synthetic hydrocarbons
  • di-n-alkyl ethers having a total of 12 to 36 carbon atoms, eg. B.
  • fatty acids especially linear and / or branched, saturated and / or unsaturated C 8 -3o fatty acids, fatty alcohols, particularly saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 4-30 carbon atoms which may be ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or propoxylated with 3-30, preferably 9-14 propylene oxide units, ester oils, ie esters of C 6 - 30- fatty acids with C 2 -3o fatty alcohols, hydroxycarboxylic acid alkyl esters, dicarboxylic acid esters such as di-n-butyl adipate and diol esters such as ethylene glycol diol or propylene glycol di (2-ethylhexanoate), symmetrical, asymmetrical or cyclic esters of carbonic acid with
  • Hardened triglyceride fats for example soybean lecithin, egg lecithin and cephalins, silicone compounds selected from decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane and silicone polymers which may, if desired, be cross-linked, e.g.
  • polydialkylsiloxanes polyalkylarylsiloxanes, ethoxylated and / or propoxylated polydialkylsiloxanes with the earlier INCI name dimethicone copolyol, and polydialkylsiloxanes containing amine and / or hydroxyl groups, preferably substances with the INCI names Dimethiconol, Amodimethicone or Trimethylsilylamodimethicone.
  • the amount used of the fatty substances is 0, 1-50 wt.%, Preferably 0.1-20 wt.% And particularly preferably 0, 1-15 wt.%, Each based on the total skin treatment agent.
  • antioxidants are antioxidants, preservatives, solvents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol, glycerol and diethylene glycol, adsorbents and fillers such as talc and Veegum ®, perfume oils, pigments and dyes for coloring the composition, substances for adjusting the pH Value, complexing agents such as EDTA, NTA, ß-Alanindiessigklare and phosphonic acids, propellants such as propane-butane mixtures, pentane, isopentane, isobutane, N 2 0, dimethyl ether, C0 2 and air.
  • solvents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol, glycerol and diethylene glycol
  • adsorbents and fillers such as talc and Veegum ®
  • perfume oils pigments and dyes for coloring the composition

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une combinaison constituée d'au moins un composé d'acide 2-méthyl-1,4,5,6-tétrahydro-4 pyrimidine carboxylique ou de ses dérivés et d'au moins un extrait d'algues bleues, ainsi qu'éventuellement d'au moins un polysaccharide contenant du fucose (notamment sous la forme d'un des agents cosmétiques des revendications 1 à 6), ladite combinaison stimulant la synthèse de la filaggrine et/ou de la transglutaminase et/ou de l'involucrine dans l'épiderme. Cette combinaison a pour effet de renforcer la barrière de la peau.
PCT/EP2012/071820 2011-12-22 2012-11-05 Utilisation d'une combinaison d'acide 2-méthyl-1,4,5,6-tétrahydro-4 pyrimidine carboxylique ou de son dérivé et d'un extrait d'algues bleues pour augmenter la fonction barrière de la peau WO2013091974A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011089582A DE102011089582A1 (de) 2011-12-22 2011-12-22 Verwendung von einer Kombination von 2-Methyl-1,4,5,6-tetrahydro-4-pyrimidincarbonsäure oder deren Derivat und einem Blaualgenextrakt zur Steigerung der Hautbarrierefunktion
DE102011089582.5 2011-12-22

Publications (2)

Publication Number Publication Date
WO2013091974A2 true WO2013091974A2 (fr) 2013-06-27
WO2013091974A3 WO2013091974A3 (fr) 2013-08-15

Family

ID=47137721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/071820 WO2013091974A2 (fr) 2011-12-22 2012-11-05 Utilisation d'une combinaison d'acide 2-méthyl-1,4,5,6-tétrahydro-4 pyrimidine carboxylique ou de son dérivé et d'un extrait d'algues bleues pour augmenter la fonction barrière de la peau

Country Status (2)

Country Link
DE (1) DE102011089582A1 (fr)
WO (1) WO2013091974A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265477A (zh) * 2016-09-28 2017-01-04 珠海姗拉娜化妆品有限公司 一种用于美白护肤品的组合物
CN107184410A (zh) * 2017-04-28 2017-09-22 广州瑞誉化工科技有限公司 一种具有激素依赖性皮炎修复功能的润肤霜

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3015283B1 (fr) * 2013-12-23 2016-12-09 Oreal Composition comprenant une forte teneur d'hydrolat

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671161A1 (fr) 1993-12-14 1995-09-13 Marbert GmbH Ectoine et dérivés de l'ectoine comme agents hydratants dans des compositions cosmétiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10059107A1 (de) * 1999-12-23 2001-06-28 Henkel Kgaa Extrakt aus der Blaualge Spirulina und seine Verwendung in kosmetischen und dermatologischen Mitteln zur Haut- und Körperpflege
DE10014632A1 (de) * 2000-03-24 2001-09-27 Merck Patent Gmbh Verwendung von Ectoin oder Ectoin-Derivaten zum Schutz der Streßproteine in der Haut
DE102006062566A1 (de) * 2006-12-29 2008-07-03 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen gegen unreine Haut und/oder Akne
DE102008061045A1 (de) * 2008-12-11 2009-10-08 Henkel Ag & Co. Kgaa Verwendung von epsilon-Viniferin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671161A1 (fr) 1993-12-14 1995-09-13 Marbert GmbH Ectoine et dérivés de l'ectoine comme agents hydratants dans des compositions cosmétiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. M. ELIAS: "Structure and Function of the Stratum Corneum Permeability Barrier", DRUG DEV. RES., vol. 13, 1988, pages 97 - 105

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265477A (zh) * 2016-09-28 2017-01-04 珠海姗拉娜化妆品有限公司 一种用于美白护肤品的组合物
CN107184410A (zh) * 2017-04-28 2017-09-22 广州瑞誉化工科技有限公司 一种具有激素依赖性皮炎修复功能的润肤霜

Also Published As

Publication number Publication date
WO2013091974A3 (fr) 2013-08-15
DE102011089582A1 (de) 2013-06-27

Similar Documents

Publication Publication Date Title
EP2275078B1 (fr) Compositions cosmétiques et dermatologiques à base de (2-hydroxyéthyl)urée
DE60303429T2 (de) Kosmetische und/oder dermatologische Verwendung einer Zusammensetzung, die mindestens einen oxidationsempfindlichen, hydrophilen, durch mindestens einem Maleinsäurenhydrid-Copolymer stabilisierten Wirkstoff enthält
DE102004032734A1 (de) Präbiotisch wirksame Substanzen für Deodorantien
DE102005063063A1 (de) Kosmetische Zusammensetzungen zur Hautmattierung
EP1576949A1 (fr) Combinaison des lipides beurre de karité et beurre de cacao pour traiter la peau cendreuse
DE102005022625A1 (de) Verwendung von Taurin zur Steigerung der epidermalen Lipidsynthese
DE19834814A1 (de) Kosmetische und dermatologische Zubereitungen mit einem wirksamen Gehalt an Gallensäuren, ihren Salzen und/oder ihren Derivaten
EP1813252A1 (fr) Composition cosmétique pour la matage du cuir chevelu
WO2013091974A2 (fr) Utilisation d'une combinaison d'acide 2-méthyl-1,4,5,6-tétrahydro-4 pyrimidine carboxylique ou de son dérivé et d'un extrait d'algues bleues pour augmenter la fonction barrière de la peau
EP2462919B1 (fr) Combinaison de principes actifs synergétiques pour la protection de la peau contre le rayonnement IR
DE102014211205A1 (de) Wirkstoffkombination für tiefenwirksamen Lifting-Effekt
EP1175897A2 (fr) Formulation cosmétique ou dermatologique pour traiter et refroidir la peau après un bain de soleil
WO2013091977A2 (fr) Utilisation d'une association de taurine et de protéine de levure hydrolysée pour augmenter la synthèse épidermique de lipides
DE102004034691A1 (de) Verwendung von Siderophoren gegen Geruchskeime
US20230112943A1 (en) Topically administrable lyzate of dedifferentiated cells of the plant helichrysum stoechas for moisturizing the skin
DE102011089558A1 (de) Neue Verwendungen von Trimethylglycin und Harnstoffderivaten
DE19723733A1 (de) Kosmetische und dermatologische Emulsionen, enthaltend Alkylglucoside und erhöhte Elektrolytkonzentrationen
DE19834812A1 (de) Verwendung von Sterolderivaten in kosmetischen und dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE102013219673A1 (de) Verwendung einer kosmetischen Zusammensetzung zur Verminderung von Alterserscheinungen der Haut
EP2745832B1 (fr) Produit de soin cutané pour le traitement des peaux matures
DE102014212055A1 (de) Kosmetische Verwendung einer Kombination aus Glycinalkylester, einer speziellen Tocol-Verbindung und zweier Pflanzenextrakte zur Hautpflege
DE102011089269A1 (de) Kosmetische Verwendung einer Kombination spezieller alpha,omega-Diole, einer speziellen Toco-Verbindung und einer Triglyzeridfraktion der Pflanze vom Typ Butyrospermum Parkii zum Schutz und/oder zur Pflege der Haut
DE102012223100A1 (de) Kosmetische Zusammensetzung enthaltend Glycinalkylester, eine spezielle Tocol-Verbindung und Pflanzenextrakt
DE102005059050A1 (de) O/W-Emulsionen mit Polysacchariden und hydrophob modifizierten Polyolen
EP1893166B1 (fr) Microemulsions et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12781100

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12781100

Country of ref document: EP

Kind code of ref document: A2